ADMP - Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares

• Adamis Pharmaceuticals is preparing to launch a Phase II/III study with TEMPOL in COVID-19 patients. The NIH recently reported that they found TEMPOL inhibits viral replication.
• I believe TEMPOL could be a leading COVID-19 therapeutic that can be employed at all stages of the infection. I provide some background on TEMPOL.
• Adamis has a history of missing opportunities with bad decisions and regulatory blunders. I believe Adamis needs to make moves sooner rather than later for TEMPOL.
• I discuss my plans for my ADMP position as we wait for an update on ZIMHI and TEMPOL.

For further details see: